The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 1,001–1,060 of 1,060
Poli, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00002 · Cited by 81
Gokulakrishnan, K., Deepa, R., Mohan, V., & Gross, M. D. (2006) · Metabolism · doi:10.1016/j.metabol.2005.08.019 · Cited by 79
Clinical Impact of a Pharmacist‐Managed Diabetes Mellitus Drug Therapy Management Service
McCord, A. D. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.2.248 · Cited by 79
Identification and Management of Cardiometabolic Risk after Spinal Cord Injury
Nash, M. S., Groah, S. L., Gater, D. R., Dyson-Hudson, T. A., Lieberman, J. A., Myers, J., Sabharwal, S., & Taylor, A. J. (2019) · The Journal of Spinal Cord Medicine · doi:10.1080/10790268.2018.1511401 · Cited by 78
Diabetes and Coronary Heart Disease as Risk Factors for Mortality in Older Adults
Carnethon, M. R., Biggs, M. L., Barzilay, J., Kuller, L. H., Mozaffarian, D., Mukamal, K., Smith, N. L., & Siscovick, D. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.023 · Cited by 77
Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention
Ordovas, J. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27113e · Cited by 74
Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy
Keating, A. J., Campbell, K. B., & Guyton, J. R. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r509 · Cited by 74
Lifestyle-Related Risk Factors and Risk of Future Nursing Home Admission
Valiyeva, E., Russell, L. B., Miller, J. E., & Safford, M. M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.985 · Cited by 73
Ryan, A. S., Keske, M. A., Hoffman, J. P., & Nelson, E. B. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fe2be · Cited by 72
Grosso, A. F., de Oliveira, S. F., Higuchi, M. D. L., Favarato, D., Dallan, L. A. D. O., & da Luz, P. L. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-47 · Cited by 69
Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
Genser, B., & März, W. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0403-x · Cited by 68
Cardiovascular Disease in Women
Stock, E. O., & Redberg, R. (2012) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.001 · Cited by 65
Pan, S.-J., Tan, Y.-L., Yao, S.-W., Xin, Y., Yang, X., Liu, J., & Xiong, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.207 · Cited by 63
Leichman, J. G., Aguilar, D., King, T. M., Vlada, A., Reyes, M., & Taegtmeyer, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.2.336 · Cited by 64
Han, S., Jiao, J., Xu, J., Zimmermann, D., Actis-Goretta, L., Guan, L., Zhao, Y., & Qin, L. (2016) · Scientific Reports · doi:10.1038/srep31337 · Cited by 63
Combination statin-fibrate therapy: safety aspects
Franssen, R., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00917.x · Cited by 60
Hyre, A. D., Fox, C. S., Astor, B. C., Cohen, A. J., & Muntner, P. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.09.017 · Cited by 55
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m032615 · Cited by 56
Dunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52
Zhou, L., Ding, C., Wu, J., Chen, X., Ng, D. M., Wang, H., Zhang, Y., & Shi, N. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.08.005 · Cited by 53
Mehta, R., Reyes-Rodríguez, E., Yaxmehen Bello-Chavolla, O., Guerrero-Díaz, A. C., Vargas-Vázquez, A., Cruz-Bautista, I., & A. Aguilar-Salinas, C. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.868 · Cited by 52
Severity of periodontitis and metabolic syndrome: is there an association?
Gomes‐Filho, I. S., das Mercês, M. C., de Santana Passos‐Soares, J., Seixas da Cruz, S., Teixeira Ladeia, A. M., Trindade, S. C., de Moraes Marcílio Cerqueira, E., Freitas Coelho, J. M., Marques Monteiro, F. M., Barreto, M. L., et al. (2016) · Journal of Periodontology · doi:10.1902/jop.2015.150367 · Cited by 52
Kitamura, A., Noda, H., Nakamura, M., Kiyama, M., Okada, T., Imano, H., Ohira, T., Sato, S., Yamagishi, K., & Iso, H. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.7237 · Cited by 51
Bangalore, S., Fayyad, R., Kastelein, J. J., Laskey, R., Amarenco, P., DeMicco, D. A., & Waters, D. D. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.024 · Cited by 51
Natsuaki, M., Furukawa, Y., Morimoto, T., Nakagawa, Y., Ono, K., Kaburagi, S., Inada, T., Mitsuoka, H., Taniguchi, R., Nakano, A., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1356 · Cited by 49
Carter, B. L., Levy, B., Gryzlak, B., Xu, Y., Chrischilles, E., Dawson, J., Vander Weg, M., Christensen, A., James, P., & Polgreen, L. (2018) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.004188 · Cited by 46
Noda, H., Iso, H., Irie, F., Sairenchi, T., Ohtaka, E., & Ohta, H. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02183.x · Cited by 48
Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.11.009 · Cited by 46
Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0077-0 · Cited by 45
Evaluation of the American Heart Association cardiovascular disease prevention guideline for women
Hsia, J., Rodabough, R. J., Manson, J. E., Liu, S., Freiberg, M. S., Graettinger, W., Rosal, M. C., Cochrane, B., Lloyd-Jones, D., Robinson, J. G., et al. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.842385 · Cited by 45
Neutel, J. M., Bestermann, W. H., Dyess, E. M., Graff, A., Kursun, A., Sutradhar, S., & Yunis, C. (2009) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00058.x · Cited by 46
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
The effect of a dietary portfolio compared to a DASH-type diet on blood pressure
Jenkins, D. J. A., Jones, P. J., Frohlich, J., Lamarche, B., Ireland, C., Nishi, S. K., Srichaikul, K., Galange, P., Pellini, C., Faulkner, D., et al. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.08.006 · Cited by 45
Aspry, K. E., Furman, R., Karalis, D. G., Jacobson, T. A., Zhang, A. M., Liptak, G. S., & Cohen, J. D. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.004 · Cited by 41
Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0241-3 · Cited by 40
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Wong, N. D., Chuang, J., Zhao, Y., & Rosenblit, P. D. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.003 · Cited by 39
Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review
Ooi, C. P., & Loke, S. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12295 · Cited by 39
Chapter 12: Systematic Review of Prognostic Tests
Rector, T. S., Taylor, B. C., & Wilt, T. J. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1899-y · Cited by 37
Sasaki, J., Yokoyama, M., Matsuzaki, M., Saito, Y., Origasa, H., Ishikawa, Y., Oikawa, S., Itakura, H., Hishida, H., Kita, T., et al. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.8326 · Cited by 35
Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany
Böhler, S., Scharnagl, H., Freisinger, F., Stojakovic, T., Glaesmer, H., Klotsche, J., Pieper, L., Pittrow, D., Kirch, W., Schneider, H., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.025 · Cited by 34
van Hateren, K. J. J., Landman, G. W. D., Kleefstra, N., Logtenberg, S. J. J., Groenier, K. H., Kamper, A. M., Houweling, S. T., & Bilo, H. J. G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008464 · Cited by 34
The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins
Madsen, C. S., Janovitz, E., Zhang, R., Nguyen-Tran, V., Ryan, C. S., Yin, X., Monshizadegan, H., Chang, M., D’Arienzo, C., Scheer, S., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131615 · Cited by 33
The Collaborative Cardiovascular Risk Reduction in Primary Care (CCARP) Study
Evans, C. D., Eurich, D. T., Taylor, J. G., & Blackburn, D. F. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.8.766 · Cited by 32
Noda, H., Iso, H., Irie, F., Sairenchi, T., Ohtaka, E., & Ohta, H. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1016 · Cited by 32
Mark, L., Vallejo-Vaz, A. J., Reiber, I., Paragh, G., Kondapally Seshasai, S. R., & Ray, K. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.810 · Cited by 30
Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
Di Folco, U., Vallecorsa, N., Nardone, M. R., Pantano, A. L., & Tubili, C. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01936-6 · Cited by 29
Lipworth, L., Fazio, S., Kabagambe, E., Munro, H., Nwazue, V., Tarone, R., McLaughlin, J., Blot, W., & Sampson, U. (2013) · Clinical Epidemiology · doi:10.2147/clep.s53492 · Cited by 26
Role of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
Evaluation of the toxicity of Arthrospira (Spirulina) platensis extract
Hutadilok-Towatana, N., Reanmongkol, W., & Panichayupakaranant, P. (2010) · Journal of Applied Phycology · doi:10.1007/s10811-009-9499-5 · Cited by 24
Josef, P., Ali, I., Ariel, P., Alon, M., & Nimer, A. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10083409 · Cited by 22
Gender, Cardiovascular Disease, and the Sexism of Obesity ∗
Bairey Merz, C. N., Andersen, H. S., & Shufelt, C. L. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.860 · Cited by 21
Bigford, G. E., Mendez, A. J., Betancourt, L., Burns-Drecq, P., Backus, D., & Nash, M. S. (2017) · Spinal Cord Series and Cases · doi:10.1038/scsandc.2017.7 · Cited by 21
Schleyer, T., Hui, S., Wang, J., Zhang, Z., Knapp, K., Baker, J., Chase, M., Boggs, R., & Simpson, R. J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.5.544 · Cited by 19
Shahinfar, H., Bazshahi, E., Amini, M. R., Payandeh, N., Pourreza, S., Noruzi, Z., & Shab‐Bidar, S. (2021) · Phytotherapy Research · doi:10.1002/ptr.7247 · Cited by 18
Kasliwal, R. R., Bansal, M., Gupta, R., Shah, S., Dani, S., Oomman, A., Pai, V., Prasad, G. M., Singhvi, S., Patel, J., et al. (2016) · Nutrition · doi:10.1016/j.nut.2016.01.012 · Cited by 17
Chin, C. W., Gao, F., Le, T., & Tan, R. (2013) · Clinical Medicine Insights: Cardiology · doi:10.4137/cmc.s11488 · Cited by 17
Heart Rate Variability and Metabolic Syndrome in Hospitalized Patients with Schizophrenia
Lee, K., Park, J., Choi, J., & Park, C. G. (2011) · Journal of Korean Academy of Nursing · doi:10.4040/jkan.2011.41.6.788 · Cited by 15
Standards of Medical Care in Diabetes
American Diabetes Association (2005) · Diabetes Care · doi:10.2337/diacare.28.suppl_1.s4 · Cited by 2
Metabolic Syndrome: An Emerging Threat
Rahman, Q. A. A., Razzak, M. A., & Wahab, M. A. (2020) · Journal of Armed Forces Medical College, Bangladesh · doi:10.3329/jafmc.v14i2.45911 · Cited by 1
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
